Close menu




June 8th, 2021 | 08:25 CEST

Deutsche Bank, Commerzbank, Sierra Growth: Of fast money and true values

  • Investments
Photo credits: pixabay.com

Prices are rising ever more sharply. Industrialized countries have now surpassed even the emerging markets in terms of inflation. For banks, the current market phase is rewarding: investment banking has become a mainstay and the prospect of higher interest rates also gives hope for the bread-and-butter business. We look at why investors should nevertheless not bet on bank shares and what alternatives there are.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE0005140008 , DE000CBK1001 , CA8263191055

Table of contents:


    Deutsche Bank: The dark side of the shrinkage cure

    Deutsche Bank has recently been presenting itself with renewed self-confidence - after all, profits are almost as bubbly as they were in the golden age. Above all, business in the investment division is going well. Financing, takeovers, other deals - the faster capital flows around the globe, the more intermediaries like Deutsche Bank and Co. earn. The Blaubank share has also reached new territory from a chart perspective and recently left behind its downward trend, which has been intact since 2007. However, investors should be cautious, especially with such long-term trends: The recent chart breakout is hardly visible in the long-term chart. Short-term events are also likely to be more relevant for the share's performance in the coming weeks.

    However, those who take a long-term view can certainly take their cue from the chart. The signal of the chart is clear and points the way towards further price gains. However, it remains unclear how rocky the road will be and how long investors can follow this path. Like all banks, Deutsche Bank is in a quandary. While the risky investment business has long been running smoothly again, the traditional lending business lags behind. The years leading up to the major financial crisis have shown where it can lead when banks have to keep setting new records with their deals. With the bank set to lay off around a quarter of its workforce between 2016 and 2023, there is likely to be a staff shortage soon to still score with traditional banking services. Although this business is not very lucrative given the low interest rate phase, inflation rates already indicate that the framework conditions could change somewhat in a few years. Whether Deutsche Bank will be able to seize these opportunities, however, remains an open question. The Company's shrinkage and focus on investment banking harbors risks.

    Commerzbank: Digitization as a cure-all

    Commerzbank is also making cuts and plans to eliminate one in three jobs in Germany. Other topics on the agenda include becoming more digital and customer-focused. The numerous personnel disruptions at Commerzbank in recent months show that these measures were also controversial internally. There have already been several changes in 2021, both in management and on the Supervisory Board. In 2021 alone, the restructuring of the bank is expected to cost up to EUR 1 billion. From 53 years of age, employees will be able to take early retirement. However, whether the measures will bear fruit is also uncertain at Commerzbank. Several major banks have already proclaimed digital goals in recent years. But they will no longer be able to convince shareholders, especially since the competition from neo-banks has long since passed them by.

    Sierra Growth: Hot potato with attractive risk-reward ratio

    While banks have been shrinking healthily for years, secretly hoping for higher interest rates and implementing one digitalization strategy after another like lumbering tankers, investors can invest in several current trends with Sierra Growth shares without many detours. Sierra Growth focuses on the search for raw materials in Peru and the US state of Nevada. Above all, the team around CEO Sonny Janda targets gold, but silver, copper and molybdenum are also suspected on the projects of the mighty team. On the three projects in Nevada, the Company has taken rock samples some time ago and expects results to be available by early July 2021. Sierra Growth then intends to plan further work based on these results.

    Sierra Growth is a speculative micro-cap with a market capitalization of about EUR 6.5 million. Unlike large financial companies in the midst of a structural change, however, the calculation at Sierra Growth is much more straightforward: Here, it is only a matter of finding raw materials. If that succeeds, Sierra Growth launches into a new stage of development. If the search fails, it should soon be looking for new properties to explore. This hop-or-top approach offers investors the opportunity for excellent upside potential with only small capital investment, as well as a narrowly defined investment horizon. In Sierra Growth's case, investors will know as early as July what the next move will be on its Walker Lane properties in Nevada. Of course, Sierra Growth shares must also be considered highly speculative. But anyone who knows how to add such stocks to a portfolio can expect a boost in returns. The rising gold price, inflationary pressure and the positive market environment for speculative stocks, including small caps, speak for Sierra Growth.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read